AN2 Therapeutics (ANTX) officer sale covers RSU tax withholding, retains 206,554 shares

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. officer Joshua M. Eizen reported an open-market sale of 5,945 shares of common stock at $4.172 per share on July 8, 2026. A footnote explains these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units on July 1, 2026, indicating this was a tax-related disposition rather than a discretionary sale. After the transaction, Eizen held 206,554 shares directly, and this balance reflects the prior purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on March 31, 2026. The reported holdings also include unvested RSUs scheduled to vest annually over four years from various grant dates in 2024–2026, subject to continued service.

Insights

Equity compensation analyst

Small, tax-driven sale tied to RSU vesting; overall position remains large.

The filing shows Joshua M. Eizen executing an open-market sale of 5,945 shares of AN2 Therapeutics common stock at $4.172 per share on July 8, 2026. A footnote states the sale was made to satisfy tax withholding obligations triggered by RSU vesting on July 1, 2026, which is a routine administrative step rather than a discretionary portfolio move.

Following the sale, Eizen directly holds 206,554 shares, and the balance reflects the purchase of 5,000 shares through the 2022 Employee Stock Purchase Plan on March 31, 2026. Additional unvested RSUs—30,000, 31,500, 58,500, and 50,000 units from grants in 2024–2026—are scheduled to vest in annual installments over four years, contingent on continued service. The transacted shares represent only a small portion of his equity exposure, so the economic signal is limited.

Insider Trade Summary

Net Seller: 5,945 shares ($24,803)

Net Sell 1 txn

Insider Eizen Joshua M

Role See Remarks

Sold 5,945 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,945	$4.172	$25K

Holdings After Transaction: Common Stock — 206,554 shares (Direct, null)

Footnotes (1)

1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026. Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026.

Key Figures

Shares sold: 5,945 shares Sale price: $4.172 per share Shares held after transaction: 206,554 shares +5 more

8 metrics

Shares sold 5,945 shares Open-market sale on July 8, 2026 to satisfy tax withholding obligations

Sale price $4.172 per share Price for 5,945 ANTX shares sold on July 8, 2026

Shares held after transaction 206,554 shares Direct holdings of Joshua M. Eizen following the July 8, 2026 sale

ESPP purchase 5,000 shares Shares purchased under 2022 Employee Stock Purchase Plan on March 31, 2026

RSU grant A 30,000 RSUs Vest 1/4 annually over four years from January 1, 2024

RSU grant B 31,500 RSUs Vest 1/4 annually over four years from November 4, 2024

RSU grant C 58,500 RSUs Vest 1/4 annually over four years from January 1, 2025

RSU grant D 50,000 RSUs Vest 1/4 annually over four years from January 1, 2026

Key Terms

Restricted Stock Units, tax withholding obligations, Employee Stock Purchase Plan, continuous service

4 terms

Restricted Stock Units financial

"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units"

Employee Stock Purchase Plan financial

"includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

continuous service financial

"in each case subject to the Reporting Person's continuous service as of such date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 06:16 PM Accepted by SEC EDGAR 07/10/2026 - 06:15 PM Learn about SEC filing dates

FAQ

What did ANTX officer Joshua M. Eizen report in this Form 4 transaction?

Joshua M. Eizen reported selling 5,945 shares of AN2 Therapeutics (ANTX) common stock at $4.172 per share on July 8, 2026. A footnote explains the sale was made to cover tax withholding obligations from RSU vesting.

Was the ANTX Form 4 sale by Joshua M. Eizen a discretionary stock sale?

The Form 4 indicates the 5,945-share sale was used to satisfy tax withholding obligations from Restricted Stock Unit vesting. This characterization suggests a routine, tax-driven transaction rather than a purely discretionary sale decision.

How many ANTX shares does Joshua M. Eizen hold after the reported sale?

After the transaction, Joshua M. Eizen directly holds 206,554 ANTX shares. This adjusted total reflects his participation in the 2022 Employee Stock Purchase Plan, including a 5,000-share purchase completed on March 31, 2026.

What ANTX equity awards are outstanding for Joshua M. Eizen according to this filing?

The filing notes remaining RSU balances of 30,000, 31,500, 58,500, and 50,000 units. Each RSU grant vests 25% annually over four years from grant dates in 2024, 2025, and 2026, subject to continued service.

At what price were the ANTX shares sold in Joshua M. Eizen’s Form 4?

The 5,945 ANTX shares were sold at an average price of $4.172 per share. The transaction is identified as an open-market sale used to fund taxes related to Restricted Stock Unit vesting on July 1, 2026.

How is ANTX’s 2022 Employee Stock Purchase Plan mentioned in this Form 4?

A footnote states the 206,554-share post-transaction balance reflects the purchase of 5,000 shares under ANTX’s 2022 Employee Stock Purchase Plan completed on March 31, 2026, indicating ongoing employee equity participation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eizen Joshua M

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		S		5,945(1)	D	$4.172	206,554(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026.

2. Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.

3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026.

Remarks:

Chief Operating Officer and Chief Legal Officer

	/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)